stockrow
Friday 6 November 2026
Export COAG’s income statement to Excel — free account
Hemab Therapeutics Holdings, Inc.
COAG Healthcare Biotechnology
48.60
3.03
+6.65%
Follow COAG
Alert me
Hemab Therapeutics Holdings, Inc. (COAG) P/E ratio
Hemab Therapeutics Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| COAG Hemab Therapeutics Holdings, Inc. | n/m |
| MRVI Maravai LifeSciences Holdings, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| ZYME Zymeworks Inc. compare | n/m |
| SEPN Septerna, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. compare | 10.5× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)